GeneBio, CURML-UTCF Collaborate to Enhance SmileMS for Forensic Toxicology
News May 24, 2010
Geneva Bioinformatics (GeneBio) SA and the Centre Universitaire Romand de Médecine Légale – Unité de Toxicologie et Chimie Forensiques (CURML-UTCF / University Center of Legal Medicine, Lausanne-Geneva – Forensic Toxicology and Chemistry Unit) announced their collaboration to enhance the capabilities of GeneBio’s SmileMS software platform for large scale forensic toxicology studies on AB SCIEX Quadrupole Linear Ion Trap Systems. These enhancements will enable AB SCIEX users in forensic toxicology to rely on SmileMS for both further results optimization and production-compliant interactive visualization.
Developed in collaboration with major institutions such as the Swiss Institute of Bioinformatics (SIB) and Prof. Denis Hochstrasser's group at the Geneva University Hospitals, SmileMS is a versatile software for the identification of small molecules by mass spectrometry for fast routine analysis and in-depth research in application fields like Clinical, Forensics, Food Testing, Pharmaceutical, Environmental and Metabolomics.
SmileMS targets the need for automatable and versatile processes using LC-MS techniques for both targeted and unknown screening of small molecules.
The enhancements to the high throughput usage of SmileMS center on a study underway at the CURML-UTCF. Saliva from about 1000 randomly-selected drivers was collected to complete toxicological analysis using LC-MSMS on an AB SCIEX QTRAP instrument. Analyses are being performed using SmileMS, and results so far show that a number of illicit substances can be easily identified with a high level of confidence using SmileMS.
“SmileMS performs admirably in our study in conjunction with the AB SCIEX mass spectrometer,” said Dr. Marc Augsburger, Operational Manager of the CURML-UTCF. “Further fine-tuning of SmileMS in relation to our research and our routine analysis will positively benefit users in the domain of forensic toxicology; we look forward to working with GeneBio on this large scale project going forward.
“This is the logical next step for SmileMS on the road to market acceptability,” said Nasri Nahas, CEO of GeneBio. “SmileMS has been created to work in real-world situations; testing and enhancements performed in conjunction with an entity such as the CURML-UTCF on specific instruments within a targeted field will only increase the overall marketability of our software. We are happy and proud to be working with Dr. Augsburger and the team at the CURML-UTCF.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019